文献类型： 外文期刊

作者： Chai, Changpeng ¹ ; Tang, Huan ² ; Miao, Xin ³ ; Chen, Tingting ² ; Su, Yuanhui ² ; Li, Lu ¹ ; Miao, Long ¹ ; Zhang, Bo ¹ ; Wang, Zhengfeng ¹ ; Luo, Wei ¹ ; Zhang, Hui ² ; Xu, Hao ¹ ; Zhou, Wence ² ;

作者机构： 1.Lanzhou Univ, Hosp 1, Dept Gen Surg 4, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China

2.Lanzhou Univ, Clin Med Coll 2, Lanzhou 730000, Peoples R China

3.Chinese Acad Agr Sci, Lanzhou Vet Res Inst, State Key Lab Vet Etiol Biol, Key Lab Anim Virol,Minist Agr, Lanzhou 730000, Peoples R China

4.Zhejiang Chinese Med Univ, Zhejiang Prov Hosp Chinese Med, Sch Clin Med 1, Hangzhou 310006, Peoples R China

5.Lanzhou Univ, Hosp 2, Dept Gen Surg, 82 Cuiyingmen, Lanzhou 730000, Peoples R China

6.Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Peoples R China

关键词： Gallbladder cancer; Cell line; Establishment; Drug resistance

期刊名称：SCIENTIFIC REPORTS （ 影响因子：3.9； 五年影响因子：4.3 ）

ISSN： 2045-2322

年卷期： 2024 年 14 卷 1 期

页码：

收录情况： SCI

摘要： In this study, we successfully established a novel gallbladder cancer cell line, designated as GBC-X1, derived from a primary tumor of a gallbladder cancer patient. By comprehensively analyzing the cell line's phenotype, molecular characteristics, biomarkers, and histological characteristics, we confirmed that GBC-X1 serves as a valuable model for investigating the pathogenesis of gallbladder cancer and developing therapeutic agents. GBC-X1 has been continuously cultured for one year, with over 60 stable passages. Morphologically, GBC-X1 exhibits typical features of epithelial tumors. The population doubling time of GBC-X1 is 32 h. STR analysis validated a high consistency between GBC-X1 and the patient's primary tumor. Karyotype analysis revealed an abnormal hypertetraploid karyotype for GBC-X1, characterized by representative karyotypes of 98, XXXX del (4) p (12) del (5) p (21) der (10). Under suspension culture conditions, GBC-X1 efficiently forms tumor balls, while subcutaneous inoculation of GBC-X1 cells into NXG mice leads to xenograft formation with a rate of 80%. Drug sensitivity testing demonstrated that GBC-X1 is resistant to oxaliplatin and sensitive to 5-FU, gemcitabine, and paclitaxel. Immunohistochemistry revealed positive expression of CK7, CK19, E-cadherin, MMP-2, CD44, SOX2, and TP53 in GBC-X1 cells, weak positive expression of Vimentin, and a Ki67 positive rate of 35%. Our research highlights GBC-X1 as a novel gallbladder cancer cell line and emphasizes its potential as an effective experimental model for investigating the pathogenesis of gallbladder cancer and drug development.